Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Surging measles cases are 'fire alarm' warning that other diseases could be next - 2The Force of Systems administration: Individual Examples of overcoming adversity
- 3Major Scottish gangland figure Steven Lyons arrested in Bali
- 4Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 5Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- Israel and Iran continue tit-for-tat attacks
- Prehistoric wolf’s gut frozen in time reveals an ice age giant
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- 7 Moves toward a Sound and Dynamic Way of life
- Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- 'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community'
- 5 Most Expected Film Delivery
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Esteem Stuffed Gaming Workstations to Consider
